Target intelligence / Profile preview

Cell–extracellular matrix adhesion interface (Cell–ECM interface) (Cell–ECM interface)

Target
Cell–ECM interface
Molecular classification
Receptor, Other
01

Overview

The Cell–extracellular matrix (ECM) adhesion interface is a complex biological structure that facilitates physical attachment and biochemical communication between a cell and its surrounding matrix. This interface is primarily mediated by the integrin family of transmembrane receptors, which cluster into specialized sites known as focal adhesions or hemidesmosomes (Hynes, R. O., Cell, 2002; Geiger, B., et al., Nat Rev Mol Cell Biol, 2009). These structures act as mechanosensors, translating physical forces from the ECM into intracellular chemical signals that regulate essential processes such as cell survival, migration, and differentiation (Geiger, B., et al., Nat Rev Mol Cell Biol, 2009; Winograd-Katz, S. E., et al., Nat Rev Mol Cell Biol, 2014). In many diseases, including cancer and fibrosis, the Cell–ECM interface is dysregulated, promoting tumor invasion, metastasis, and pathological tissue remodeling (Desgrosellier, J. S., & Cheresh, D. A., Nat Rev Cancer, 2010). Therapeutic targeting of this interface typically involves small molecules or monoclonal antibodies designed to block integrin-ligand interactions, thereby disrupting the signaling and migratory capabilities of pathogenic cells (Winograd-Katz, S. E., et al., Nat Rev Mol Cell Biol, 2014; Desgrosellier, J. S., & Cheresh, D. A., Nat Rev Cancer, 2010).

Other names
Focal adhesionHemidesmosomeCell-matrix junctionIntegrin-mediated adhesion complexCell-ECM junction
02

Mechanism of action

Inhibition of integrin-mediated cell attachment to extracellular matrix components; blockade of outside-in and inside-out signaling pathways.

03

Biological functions

Signal transductionCell migrationCell proliferationOther
04

Disease associations

CancerInflammationCardiovascular diseaseOther
05

Safety considerations

Bleeding riskIncreased risk of infectionProgressive multifocal leukoencephalopathy (PML)Impaired wound healing
06

Interacting drugs

Abciximab

6 more in the full profile.

07

Biomarkers

Integrin alpha-v beta-3 expressionFocal Adhesion Kinase (FAK) phosphorylationSoluble VCAM-1

Beyond the preview

Go deeper on Cell–extracellular matrix adhesion interface (Cell–ECM interface) (Cell–ECM interface).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cell–extracellular matrix adhesion interface (Cell–ECM interface) (Cell–ECM interface).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call